Takeda: Inflammatory Bowel Diseases trials

The registry lists 24 Inflammatory Bowel Diseases studies with Takeda as lead sponsor. 1 are open to participants now and 8 have results posted.

Phase 1 1Phase 3 2No phase 21(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South KoreaRecruitingNCT05428345
• A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)CompletedNCT04873700Results posted
• Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical OutcomesCompletedNCT04567628Results posted
• Perianal Fistula (PAF) Validation and Burden of Illness StudyCompletedNCT03981939Results posted
• A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life PracticeCompletedNCT03532932Results posted
• A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD)CompletedNCT03488030Results posted
• A Retrospective Observational Study to Assess the Impact of Co-morbidities on Treatment Response in Inflammatory Bowel DiseaseCompletedNCT02861118Results posted
• Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in BrazilCompletedNCT02822235Results posted
• Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of VedolizumabCompletedNCT01981616Phase 1Results posted
• A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)CompletedNCT05596422
• A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in PolandCompletedNCT05384080
• A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in SwitzerlandCompletedNCT04989907
• A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium)CompletedNCT04959851
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World PracticeCompletedNCT04890262
• A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)CompletedNCT04885920
• A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic PouchitisCompletedNCT04799496
• Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in EuropeCompletedNCT04597905
• Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After TreatmentTerminatedNCT04102163
• A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)CompletedNCT03668249
• A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real LifeTerminatedNCT03378388
• Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging MarketsCompletedNCT03090139
• Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel DiseaseWithdrawnNCT03035058Phase 3
• A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD)CompletedNCT02986724
• Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s DiseaseCompletedNCT00475410Phase 3